Quantum biopharma announces that sentinel dosing has started for the phase-1 multiple ascending dose clinical trial for lucid-21-302 (lucid-ms) in australia

Toronto, on / accesswire / october 29, 2024 / quantum biopharma ltd. (nasdaq:qntm)(cse:qntm)(fra:0k91) ("quantum biopharma" or the "company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, huge biopharma australia pty ltd.
QNTM Ratings Summary
QNTM Quant Ranking